Larimar Therapeutics, Inc. (LRMR)
- Previous Close
6.29 - Open
6.39 - Bid 6.52 x 200
- Ask 6.56 x 200
- Day's Range
6.30 - 7.36 - 52 Week Range
2.18 - 13.68 - Volume
1,739,122 - Avg. Volume
563,376 - Market Cap (intraday)
416.019M - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-1.12 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.33
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.
www.larimartx.comRecent News: LRMR
View MorePerformance Overview: LRMR
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LRMR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LRMR
View MoreValuation Measures
Market Cap
417.30M
Enterprise Value
196.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.97
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-23.59%
Return on Equity (ttm)
-37.48%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-58.34M
Diluted EPS (ttm)
-1.12
Balance Sheet and Cash Flow
Total Cash (mrq)
226.06M
Total Debt/Equity (mrq)
2.65%
Levered Free Cash Flow (ttm)
-22.43M